Thousands of lawsuits claiming Depo-Provera is tied to the development of brain tumors could be nearing resolution. A Monday court filing revealed that Pfizer and other defendants have reached an agreement with people who have filed lawsuits to settle these cases.

The first Depo-Provera trial, which was slated for December 2026, was also removed from the schedule.

No financial details of the settlement have been revealed, and the specific details of the deal are still being finalized.

If the settlement is finalized and approved, it would represent an unusually quick result for such a wide-spanning litigation. Well over 5,000 Depo shot lawsuits are active as of this month, after the earliest cases were filed in late 2024. Other similar dangerous product lawsuits have taken years to reach resolution.

It is unclear how many of those 5,000-plus cases will be eligible to participate in the settlement.

See if You Qualify for a Lawsuit Our Partners

Our Trusted Legal Partners

Drugwatch partners with trusted law firms to help you take legal action. After submitting the form, one of Drugwatch's partners will contact you for a free case review.

simmons hanly conroy law firm logo weitz and luxenberg logo sokolove law firm logo levin papantonio rafferty law firm logo nigh goldenberg raso and vaughn law firm logo morgan & morgan logo the ferraro law firm logo meirowitz & wasserberg law firm logo

Depo-Provera Lawsuits Claim Pfizer Failed to Warn of Tumor Risk

Pfizer has faced growing claims that it failed to warn patients of a potentially heightened risk of tumors tied to use of Depo-Provera. The popular birth control shot, which was marketed around its convenience as it only requires four shorts per year, is used by millions of women.

In 2024, a study published in the BMJ found that women who use Depo-Provera could be upwards of five times more likely to develop a meningioma. These tumors, which form in the lining of the brain and spinal cord, are typically benign. But they can cause devastating health effects and may require invasive surgery to remove.

Lawsuits quickly followed after that study was released, with women claiming that their lives were upended by the effects of their tumors.

In December 2025, the Food & Drug Administration added information on meningiomas to the Depo-Provera warning label.

It is unclear when the settlement will be fully finalized. An upcoming hearing for these cases that had been scheduled to begin next week has been pushed to July 27 in light of the settlement.